PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CRC--US FDA Approves Opdivo plus Yervoy as a Treatment fo...

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CRC--US FDA Approves Opdivo plus Yervoy as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair.

U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1

FDA approves Opdivo and Yervoy for specific cancer treatments.
This approval could enhance BMY's market position and revenue potential.

u-s-food-and-drug-administration-approves-opdivo-nivolumab-plus-yervoy-ipilimumab-as-a-treatment-for-patients-with-previously-untreated-microsatellite-instability-high-or-mismatch-repair-deficient-unresectable-or-metastatic-colorectal-cancer1

U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1

FAQ

Why Bullish?

How important is it?

Why Long Term?

Related Companies

Related News